Login to Your Account

Amgen mum on next steps after T-vec OS miss in melanoma

By Marie Powers
Staff Writer

Friday, April 4, 2014
On Friday, Amgen Inc. masked disappointing findings on cancer immunotherapy talimogene laherparepvec, commonly known as T-vec, by disclosing that secondary endpoint data on overall survival (OS) in melanoma showed a “strong trend” despite a statistical miss.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription